Profile data is unavailable for this security.
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
- Revenue in USD (TTM)442.59m
- Net income in USD-613.35m
- Incorporated2011
- Employees1.28k
- LocationUltragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
- Phone+1 (415) 483-8800
- Fax+1 (415) 483-8810
- Websitehttps://www.ultragenyx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10X Genomics Inc | 625.45m | -264.30m | 2.99bn | 1.26k | -- | 4.16 | -- | 4.79 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 3.00bn | 251.00 | -- | 3.38 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 3.07bn | 124.00 | -- | 3.24 | -- | 197.71 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 3.08bn | 525.00 | -- | 6.36 | -- | 86.73 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Guardant Health Inc | 603.73m | -460.90m | 3.10bn | 1.78k | -- | 45.23 | -- | 5.14 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 3.12bn | 105.00 | -- | 70.50 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 3.13bn | 1.05k | -- | 9.07 | 388.85 | 3.26 | -0.016 | -0.016 | 4.46 | 1.61 | 2.33 | 6.68 | -- | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | -- | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.30bn | 239.00 | -- | 10.14 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.32bn | 305.00 | -- | 5.85 | -- | 125.58 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.48bn | 1.28k | -- | 24.80 | -- | 7.86 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.60bn | 999.00 | -- | -- | -- | 38.57 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.64bn | 545.00 | -- | 25.22 | -- | 14.48 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Insmed Inc | 315.49m | -746.89m | 3.68bn | 912.00 | -- | -- | -- | 11.67 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.75bn | 271.00 | 26.95 | 2.28 | 23.18 | 2.96 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
Data as of May 17 2024. Currency figures normalised to Ultragenyx Pharmaceutical Inc's reporting currency: US Dollar USD
50.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.58m | 10.42% |
| RTW Investments LPas of 31 Dec 2023 | 6.89m | 8.37% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 4.42m | 5.36% |
| Sands Capital Management LLCas of 31 Dec 2023 | 4.12m | 5.00% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.10m | 4.98% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.36m | 4.08% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.25m | 3.95% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 2.45m | 2.97% |
| ClearBridge Investments LLCas of 31 Dec 2023 | 2.38m | 2.90% |
| Alkeon Capital Management LLCas of 31 Dec 2023 | 2.24m | 2.72% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
